A carregar...
Phase I/II study of bortezomib in combination with carboplatin and bevacizumab as first line therapy in patients with advanced non-small cell lung cancer (NSCLC)
PURPOSE: To establish the maximum tolerated dose (MTD) of weekly bortezomib in combination with fixed standard doses of carboplatin and bevacizumab and to estimate the efficacy (response rate and progression free survival) and safety of combination therapy with carboplatin, bortezomib and bevacizuma...
Na minha lista:
| Main Authors: | , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2012
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3852685/ https://ncbi.nlm.nih.gov/pubmed/22534815 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JTO.0b013e31824de2fa |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|